The Effect of Switch Treatment on Liver Fibrosis and qHBsAg Levels in Patients with Chronic Hepatitis B

• Published in: Viral hepatit dergisi 2020-08, Vol.26 (2), p.69-73
• Main Authors: Yeşilyurt, Esra, Kaya, Muhammed, Dindar, Gökhan, Açıkgöz, Seyyid Bilal, Güzelbulut, Fatih, Sezikli, Hayrunnisa, Şirin, Göktuğ, Sezikli, Mesut
• Format: Article
• Language: eng ; tur
• Subjects: Antigens; Antiretroviral drugs; Biopsy; Bone density; Hepatitis B; Infections; Liver cancer; Liver cirrhosis; Liver diseases
• ISSN: 1307-9441; 2147-2939
• DOI: 10.4274/vhd.galenos.2020.2020.0008

Objectives: The aim of this study was to evaluate the relationship between clinical, biochemical, serological parameters, fibroscan imaging in terms of fibrosis and quantitative hepatitis B surface antigen (qHBsAg) levels in patients with chronic hepatitis B (CHB) infection whose treatment has been switched from LAM to TDF. Materials and Methods: The study included 19 patients with CHB and under the LAM treatment. The gender, age, comorbidity, medications, routine laboratuary, creatinine clearance, bone mineral density, transient elastography for stage of liver fibrosis and qHBsAg level were examined. Results: Ten of 19 patients were female and 9 were male. When the qHBsAg titers of the patients at 6th and 12th months were compared, there was a statistically significant decrease in qHBsAg titers of the patients after the 12th month. There was a significant decrease in liver fibrosis measurements at the 12th month of treatment change. There was a statistically significant positive correlation between qHBsAg titers and fibroscan values at baseline and 12th month. Conclusion: In this study, the replacement of LAM with TDF may prevent the resistance problem, and also the decrease in fibrosis values and/or qHBsAg levels may contribute to the prevention of HCC and cirrhosis have been showed.